A case series of patients with blastic plasmacytoid dendritic cell neoplasm; a report from Iran

  • سال انتشار: 1396
  • محل انتشار: نوزدهمین همایش سالانه و دومین همایش بین المللی آسیب شناسی و طب آزمایشگاه
  • کد COI اختصاصی: ACPLMED19_044
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 462
دانلود فایل این مقاله

نویسندگان

Mehdi Montazer

Department of Hematopathology, Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran

Freidoon Solhjoo

Department of Hematopathology, Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran

Maral Mokhtari

Department of Hematopathology, Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran

Ahmad Monabati

Department of Hematopathology, Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran

چکیده

Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy, with both cutaneous and hematopoietic involvement, which had been known as blastic natural killer cell leukemia/lymphoma in the past. However, it is now known to be derived from the recently recognized subtype of dendritic cells named plasmacytoid dendritic cells. To our knowledge, this is the first report from Iran. Case presentation: Herein, we present three cases of BPDCN diagnosed in the pasttwo years and discuss the different available diagnostic modalities including flow cytometry, immunohistochemistry and cytogenetics. BPDCN shares significant mmunophenotypic characteristics with T/NK cell lymphoma/leukemia and the dual reactivity for CD4 and CD56 in BPDCN cannot sufficiently distinguish these two entities. At the point, more specific markers for BPDCN, such as CD123, are essentially helpful in this differentiation. Lineage-specific markers were negative, including myeloid (CD13, CD33, CD117, MPO), monocytic (CD11b, CD14, CD64), megakaryocytic (CD61), B-cell (CD19, CD10, CD20) and T-cell (CD3) antigens. BPDCN is a diagnosis of suspicion and can be easily missed approaching the patients with acute leukemia. This is also true while dealing with cutaneous hematopoietic infiltrates where a correct diagnosis of BPDCN is essentially important because of the high probability of future bone marrow dissemination. Discussion: Overall, we believe that BPDCN is a rare diagnosis that should not bemissed. Currently available immunohistochemical and flow cytometric markers are of great aid, but the main key to solve the problem of BPDCN is clinicopathologic suspicion.

کلیدواژه ها

Leukemia, Blastic plasmacytoid dendritic cell neoplasm, Immunophenotyping, Iran

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.